Richard Mohs, AgeneBio Vice President of Clinical Development, Presents at the 15th Annual CTAD Conference

HOPE4MCI Trial Targeting Hippocampal Overactivity for the treatment of Mild Cognitive Impairment due to Alzheimer’s disease with AGB101: Baseline Tau and MRI imaging characteristics Richard Mohs 1 , Sharon Rosenzweig-Lipson 1 , Arnold Bakker2 , Elizabeth Chang2 , Nisha Rani2 , Russell Barton1 , Michela Gallagher1, 2 1 AgeneBio, Inc – Baltimore (United States), 2 Johns…